Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis

2019140 citationsJournal Articlegreen Open Access

Authors

Paolo Raggi · University of Alberta

Antonio Bellasi · Ospedale Papa Giovanni XXIII

David A. Bushinsky · University of Rochester Medical Center

Jordi Bover · Puigvert Foundation

Mariano Rodríguez · Hospital Universitario Reina Sofía

Markus Ketteler · Robert Bosch Hospital

Smeeta Sinha

Abstract

Compared with placebo, SNF472 significantly attenuated the progression of coronary artery calcium and aortic valve calcification in patients with end-stage kidney disease receiving hemodialysis in addition to standard care. Future studies are needed to determine the effects of SNF472 on cardiovascular events. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02966028.

Topics & Keywords

Parathyroid Disorders and Treatments Trace Elements in Health Chronic Kidney Disease and Diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 141, Issue 9, pp. 728-739

DOI: 10.1161/circulationaha.119.044195

Field-Weighted Citation Impact: 11.37